47 results on '"Chen, Zhe-Sheng"'
Search Results
2. Correction: Bridging cultures: Chinese elements in scientific illustrations
3. Research progress of antibody–drug conjugates in gynecologic cancer
4. Bridging cultures: Chinese elements in scientific illustrations
5. Understanding the Novel Approach of Nanoferroptosis for Cancer Therapy
6. Artemisia argyi H. Lév. & Vaniot: a comprehensive review on traditional uses, phytochemistry, and pharmacological activities
7. Synthesis and clinical application of new drugs approved by FDA in 2022
8. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
9. Epigenetic modification of m6A regulator proteins in cancer
10. Gold nanoparticles and gold nanorods in the landscape of cancer therapy
11. Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair
12. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
13. Advancements in nanoparticle-based treatment approaches for skin cancer therapy
14. New opportunities for RGD-engineered metal nanoparticles in cancer
15. Recent review of COVID-19 management: diagnosis, treatment and vaccination
16. Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera
17. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN
18. PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study
19. m6A modification: recent advances, anticancer targeted drug discovery and beyond
20. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma
21. Signaling pathways and therapeutic interventions in gastric cancer
22. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
23. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells
24. Microbiota in health and diseases
25. Proteomics technologies for cancer liquid biopsies
26. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
27. Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis
28. Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure
29. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer
30. Isolation, bioassay and 3D-QSAR analysis of 8-isopentenyl flavonoids from Epimedium sagittatum maxim. as PDE5A inhibitors
31. Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p
32. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma
33. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
34. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
35. MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer
36. Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
37. Drug resistance: from bacteria to cancer
38. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer
39. Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing
40. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications
41. Long non-coding RNAs regulate drug resistance in cancer
42. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
43. Multidrug Resistance Proteins (MRPs) and Cancer Therapy
44. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells
45. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production
46. ABCC10, ABCC11, and ABCC12
47. MRP Subfamily Transporters and Resistance to Anticancer Agents
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.